Beacon pharma incurs loss in Jan-Mar
At the end of the first three quarters of the fiscal year 2023-24, its earnings per share was Tk2.38, lowering from Tk2.57 in the same period a year ago
At the end of the first three quarters of the fiscal year 2023-24, its earnings per share was Tk2.38, lowering from Tk2.57 in the same period a year ago